Off-Label Is Legal. Unapproved Is Not. The Difference Decides Everything.

2026-08-01 · CompliancePilotAI.io

Ask a room full of practice owners whether off-label use is allowed and you'll get a confident yes. Ask the follow-up — does that cover the exosome serum? — and the room goes quiet. That gap is where most of the enforcement risk in aesthetic medicine actually lives.

Off-label prescribing is legal. Full stop.

A licensed physician may prescribe an FDA-approved drug for a use, dose, population, or route the approval doesn't cover. FDA regulates products and the companies that manufacture them; it does not regulate the practice of medicine. Exercising medical judgment about an approved product is what physicians are licensed to do.

This is not a grey area and it is not a loophole. It is ordinary medicine — a large share of prescriptions written in the US are off-label.

The word that does the work is "approved"

Here is the distinction almost everyone collapses:

	Off-label	Unapproved
What it is	An FDA-approved product, used differently	No approved product exists at all
Example	An approved injectable used at an unlisted site	Exosome preparations, most research peptides, compounded growth-factor gels
Prescribing	Lawful, with judgment and consent	Not a question of labeling — the product itself is outside the approval system
"It's off-label" as a defense	Legitimate	Meaningless — there is no approval to be "off" of

That last row is the whole article. Reaching for "off-label" to justify a product that was never approved isn't a weak argument; it's a category error, and it reads as one to a regulator.

Even when the prescribing is lawful, the advertising may not be

Nobody receives a warning letter for a decision made in an exam room. They receive one for a web page. Four separate exposures attach to your marketing, not your medicine:

Intended use. Advertising an off-label use is you stating publicly, in writing, what you intend the product to do. That is the mechanism that classifies products under the FD&C Act, and it can pull an approved product into an unapproved-use claim.
FTC substantiation. Any efficacy claim needs competent and reliable scientific evidence. Approval status is irrelevant to that test — and off-label claims usually rest on thinner evidence, which makes them harder to defend, not easier.
Your state board. Boards enforce advertising rules, standard of care, and informed consent independently of anything FDA does. Patients generally should be told when a use is off-label, and that conversation should be documented.
Billing. If a government payer is involved, off-label use without recognised compendia support raises False Claims Act exposure. Largely moot for cash-pay aesthetics; very much live in pain management and orthopedics.

Devices split the same way

Using a cleared device off-label is practice of medicine. Marketing an indication the device was never cleared for is promotion of an uncleared device — a different and worse problem. FDA has enforced exactly this against energy-device marketing, writing to manufacturers that it was unable to identify any clearance or approval for their devices as marketed for the uses being advertised.

The one question to ask

Before you write "off-label" anywhere — internally or externally — answer this:

Is there an FDA-approved product for this substance, in this form?

If yes: you may prescribe off-label. Keep the off-label use out of your advertising, keep every public claim substantiated, and document consent.

If no: "off-label" is the wrong word entirely. The question isn't how to phrase the page. It's whether to offer the service at all — and that's a conversation with counsel, not a copy edit.

Educational information about publicly available regulatory frameworks — not legal advice. Items requiring escalation should be reviewed by qualified healthcare counsel.